Optimal Role of Patient Organisations in Drug Development

24 Mar 2011

Amsterdam, The Netherlands

Industry could benefit from collaboration with patient organisations at an early stage in drug development. It is the members of these organisations who participate in clinical trials and will ultimately be the ones to decide whether the tested drugs are beneficial to them to an extent that EMA and FDA will allow these drugs.

This will be the Kick-Off meeting for a discussion on how partnership with patient organisations can contribute to more efficient drug development.

The attendance is expected to exceed 200 and meeting participants will consist of Patient Organisations, Academia, Industry along with Policy Makers.

Book your place now via the Conference website as early registration is recommended.

De Rode Hoed,
The Netherlands